Seminars in Nuclear Medicine
Volume 37, Issue 5 , Pages 340-356 , September 2007

Differentiated Pediatric Thyroid Cancer: Correlates With Adult Disease, Controversies in Treatment

  • Marguerite T. Parisi, MD, MS Ed

      Affiliations

    • Department of Radiology, Children’s Hospital and Regional Medical Center, Seattle, WA.
    • Department of Radiology, University of Washington, Seattle, WA.
    • Corresponding Author InformationAddress reprint requests to Marguerite T. Parisi, MD, MS Ed, Department of Radiology R5417, Children’s Hospital and Regional Medical Center, 4800 Sand Point Way NE, Seattle, WA 98105.
    • ,
  • David Mankoff, MD, PhD

      Affiliations

    • Department of Radiology, University of Washington, Seattle, WA.
    • Seattle Cancer Care Alliance, Seattle, WA.

References 

  1. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297–306
  2. Ries LAG, Eisner MP, Kosary CL, et al: 2000 SEER Cancer Statistics Review, 1973-1977. Bethesda, MD, National Cancer Institute.
  3. Pacini F. Thyroid cancer in children and adolescents. J Endocrinol Invest. 2002;25:572–573
  4. Kebebew E, Ituarte PHG, Siperstein AE, et al. Medullary thyroid carcinoma (Clinical characteristics, treatment, prognostic factors, and a comparison of staging systems). Cancer. 2000;88:1139–1148
  5. Buckwalter JA, Gurll NJ, Thomas CG. Cancer of the thyroid in youth. World J Surg. 1981;5:15–25
  6. Harach HR, Williams ED. Childhood thyroid cancer in England and Wales. Br J Cancer. 1995;72:777–783
  7. DeKeyser LFM, Van Herle AJ. Differentiated thyroid cancer in children. Head Neck Surg. 1985;8:100–114
  8. Winship T, Rosvoll RV. Childhood thyroid carcinoma. Cancer. 1961;14:734–743
  9. Ries LAG, Harkins D, Krapcho M, et al (eds): SEER Cancer Statistics Review, 1975-2003, National Cancer Institute, Bethesda, MD. Available at: http://seer.cancer.gov/csr/1975_2003/. Based on November 2005 SEER data submission, posted to the SEER web site, 2006
  10. Bernstein L, Gurney JG. Carcinomas and other malignant epithelial neoplasms. ICCC XI. Pediatric Monograph. In:  Ries LAG,  Smith MA,  Gurney JG, et al. editor. Cancer Incidence and Survival Among Children and Adolescents. Bethesda, MD: National Cancer Institute; 1999;United States SEER Program 1975-1995, SEER Program NIH Pub. No. 99-4649
  11. Waguespack S, Wells S, Ross J, et al. Thyroid Cancer (SEER AYA Monograph). In:  Bleyer A,  O’Leary M,  Barr R, et al. editor. Cancer Epidemiology in Older Adolescents and Young Adults 15-29 Years of Age, Including SEER Incidence and Survival: 1975-2000. Bethesda, MD: National Cancer Institute; 2006;NIH Pub. NO. 06-5767
  12. Crile G. Carcinoma of the thyroid in children. Ann Surg. 1959;150:959–964
  13. Duffy BJ, Fitzgerald PJ. Cancer of the thyroid in children: A report of 28 cases. J Clin Endocrinol Metab. 1950;10:1296–1308
  14. LaQuaglia MP, Telander RL. Differentiated and medullary thyroid cancer in childhood and adolescence. Semin Pediatr Surg. 1997;6:42–49
  15. Winship T, Rosvall RV. Thyroid carcinoma in childhood: Final report on a 20 year study. Clin Proc Children’s Hosp Washington DC. 1970;26:327–349
  16. Schlumberger M, de Vathaire F, Travagli JP, et al. Differentiated thyroid carcinoma in childhood: long term follow-up of 72 patients. J Clin Endocrinol Metab. 1987;65:1088–1094
  17. Ceccarelli C, Pacini F, Lippi F, et al. Thyroid cancer in children and adolescents. Surgery. 1988;104:1143–1148
  18. Zimmerman D, Hay ID, Gough IR, et al. Papillary thyroid carcinoma in children and adults: Long-term follow-up of 1039 patients conservatively treated at one institution over three decades. Surgery. 1988;104:1157–1166
  19. Samuel AM, Sharma SM. Differentiated thyroid carcinomas in children and adolescents. Cancer. 1991;67:2186–2190
  20. McClellan DR, Francis GL. Thyroid cancer in children, pregnant women and patients with Graves’ disease. Endocrinol and Metab Clin North Am. 1996;25:27–48
  21. Dottorini ME, Vignati A, Mazzucchelli L, et al. Differentiated thyroid carcinoma in children and adolescents: A 37 year experience in 85 patients. J Nucl Med. 1997;38:669–675
  22. Sykes AJ, Gattamameni HR. Carcinoma of the thyroid in children: A 25 year experience. Med Pediatr Oncol. 1997;29:103–107
  23. Landau D, Vini L, Hern RA, et al. Thyroid cancer in children: The Royal Marsden Hospital experience. Eur J Cancer. 2000;36:214–220
  24. Ben Arush MW, Stein ME, Perez Nahum M, et al. Pediatric thyroid carcinoma: 22 years of experience at the Northern Israel Oncology Center (1973-1995). Pediatr Hematol Oncol. 2000;17:85–92
  25. Bauer AJ, Tuttle RM, Francis GL. Differentiated thyroid carcinoma of children and adolescents. Endocrinologist. 2002;12:135–142
  26. Arici C, Erdogan O, Altunbas H, et al. Differentiated thyroid carcinoma in children and adolescents. Horm Res. 2002;57:153–156
  27. La Quaglia MP, Corbally MT, Heller G, et al. Recurrance and morbidity in differentiated thyroid cancer in children. Surgery. 1988;104:1149–1156
  28. Alessandri AJ, Goddard KJ, Blair GK, et al. Age is the major determinant of recurrence in pediatric differentiated thyroid carcinoma. Med Pediatr Oncol. 2000;35:41–46
  29. Brink JS, van Heerden JA, McIver B, et al. Papillary thyroid cancer with pulmonary metastases in children: long term prognosis. Surgery. 2000;128:881–887
  30. Kowalski LP, Fihlo JG, Pinto CAL, et al. Long-term survival rates in young patients with thyroid carcinoma. Arch Otolaryngol Head Neck Surg. 2003;129:746–749
  31. Jhiang SM, Fithian L, Weghorst CM, et al. RET mutation screening in MEN2 patients and discovery of a novel mutation in a sporadic medullary thyroid carcinoma. Thyroid. 1996;6:115–121
  32. Pacini F, Elisei R, Romei C, et al. RET proto-oncogene mutations in thyroid carcinomas: Clinical relevance. J Endocrinol Invest. 2000;23:328–338
  33. Sadetzki S, Calderon-Margalit R, Modan B, et al. Ret/PTC activation in benign and malignant thyroid tumors arising in a population exposed to low-dose external beam irradiation in childhood. J Clin Endocrinol Metab. 2004;89:2281–2289
  34. Martins RG, Rajendran JG, Capell P, et al. Medullary thyroid cancer—options for systemic therapy of metastatic disease?. J Clin Oncol. 2006;24:1653–1655
  35. Clark DE. Association of irradiation with cancer of the thyroid in children and adolescents. JAMA. 1955;159:1007–1009
  36. Parker LN, Belsky JL, Yamamoto T, et al. Thyroid carcinoma after exposure to atomic radiation: a continuing survey of a fixed population Hiroshima and Nagasaki, 1958-1971. Ann Intern Med. 1974;80:600–604
  37. Johnson CJ. Cancer incidence in an area of radioactive fallout downwind from the Nevada test site. JAMA. 1984;251:230–236
  38. Hamilton TE, van Belle G, LoGerfo JP. Thyroid neoplasia in Marshall Islanders exposed to nuclear fallout. JAMA. 1987;258:629–636
  39. Morimoto I, Yoshimoto Y, Sato K, et al. Serum TSH, thyroglobulin and thyroidal disorders in atomic bomb survivors exposed in youth: 30 year follow-up study. J Nucl Med. 1987;28:1115–1122
  40. Nikiforov Y, Gnepp DR. Pediatric thyroid cancer after the Chernobyl Disaster. Cancer. 1994;74:748–766
  41. Kazakov VS, Demidchik EP, Astakhova LN. Thyroid cancer after Chernobyl. Nature. 1992;359:21
  42. Acharya S, Sarafoglou K, La Quaglia M, et al. Thyroid neoplasms after therapeutic radiation for malignancies during childhood and adolescence. Cancer. 2003;97:2397–2403
  43. Tucker MA, Jones PH, Boice JD, et al. Therapeutic radiation at a young age is linked to secondary thyroid cancer (The Late Effects Study Group). Cancer Res. 1991;51:2885–2888
  44. Smith MB, Xue H, Strong L, et al. Forty year experience with second malignancies after treatment of childhood cancer: Analysis of outcome following the development of the secondary malignancy. J Pediatr Surg. 1993;28:1342–1349
  45. Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five-year survivors of childhood cancer: Childhood cancer survivor study. J Natl Cancer Inst. 2001;93:618–629
  46. Sigurdson AJ, Ronckers CM, Mertens AC, et al. Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): A nested case-control study. Lancet. 2005;365:2014–2023
  47. Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997;336:897–904
  48. Cohen A, Rovelli A, van Lint MT, et al. Secondary thyroid carcinoma after allogeneic bone marrow transplantation during childhood. Bone Marrow Transplant. 2001;28:1125–1128
  49. Kyllonen L. Cancer incidence in a kidney transplanted population. Tranplant Int. 2000;13(suppl 1):S394–S398
  50. Fisher DA. Thyroid nodules in children and their management. J Pediatr. 1976;89:866–868
  51. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med. 1993;328:553–559
  52. Lafferty AR, Batch JA. Thyroid nodules in children and adolescence: Thirty years of experience. J Pediatr Endocrinol Metab. 1997;10:479–486
  53. McHenry C, Smith M, Lawrence AM, et al. Nodular thyroid disease in children and adolescents: A high incidence of carcinoma. Am Surg. 1998;54:444–447
  54. Gerber ME, Bennett E, Maddalozzo J. Thyroid cancer in children. 2007;Available at: Emedicine.com/ent/topic724.htm. Accessed May 21
  55. Hung W, Anderson KD, Chandra RS, et al. Solitary thyroid nodules in 71 children and adolescents. J Pediatr Surg. 1992;27:1407–1409
  56. Ogilivie JB, Piatigorski EJ, Clark OH. Current status of fine needle aspiration for thyroid nodules. Adv Surg. 2006;40:223–238
  57. Hopwood NJ, Kelch RP. Thyroid masses: Approach to diagnosis and management in childhood and adolescence. Pediatr Rev. 1993;14:481–487
  58. Telander RL, Moir CR. Medullary thyroid carcinoma in children. Semin Pediatr Surg. 1994;3:188–193
  59. Desjardins JG, Khan AH, Montupet P, et al. Management of thyroid nodules in children: a 20 year experience. J Pediatr Surg. 1987;22:736–739
  60. Yastovich A, Laberge JM, Rodd C, et al. Cystic thyroid lesions in children. J Pediatr Surg. 1998;33:866–870
  61. Degnan BM, McClellan DR, Francis GL. An analysis of fine-needle aspiration of the thyroid in children and adolescents. J Pediatr Surg. 1996;31:903–907
  62. Cox MR, Marshall SG, Spence RA. Solitary thyroid nodule: A prospective evaluation of nuclear scanning and ultrasonography. Br J Surg. 1991;78:90–93
  63. Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metabol. 2001;86:1447–1463
  64. Mazzafferi EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88:1433–1441
  65. Mandel SJ, Shankar LK, Benard F, et al. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer. Clin Nucl Med. 2001;26:6–9
  66. Gerhard SK, Cavalieri RR. I-123 diagnostic thyroid tumor whole-body scanning with imaging at 6, 24, and 48 hours. Clin Nucl Med. 2002;27:1–8
  67. Urhan M, Dadparvar S, Mavi A, et al. Iodine-123 as a diagnostic imaging agent in differentiated thyroid carcinoma: a comparison with iodine-131 post-treatment scanning and serum thyroglobulin measurement. Eur J Nucl Med Mol Imaging. 2007;34:1012–1017
  68. Brenner W. Is thyroid stunning a real phenomenon or just fiction?. J Nucl Med. 2002;43:835–836
  69. Robbins RJ, Robbins AK. Clinical review 156: Recombinant human thyrotropin and thyroid cancer management. J Clin Endocrinol Metab. 2003;88:1933–1938
  70. Ladenson PW, Braverman LE, Mazzaferri EL, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med. 1997;337:888–896
  71. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 1999;84:3877–3885
  72. Iorcansky S, Herzovich V, Qualey RR, et al. Serum thyrotropin (TSH) levels after recombinant human TSH injections in children and teenagers with papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90:6553–6555
  73. Hoe FM, Charron M, Moshang T. Use of the recombinant human TSH stimulated thyroglobulin level and diagnostic whole body scan in children with differentiated thyroid cancer. J Pediatr Endocrinol Metabol. 2006;19:25–30
  74. Schluter B, Bohuslavizki KH, Beyer W, et al. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131-I scan. J Nucl Med. 2001;42:71–76
  75. Frilling A, Tecklenborg K, Gorges R, et al. Preoperative diagnostic value of [18F] Fluoro deoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg. 2001;234:804–811
  76. McDougall IR, Davidson J, Segall GM. Positron emission tomography of the thyroid, with emphasis on thyroid cancer. Nucl Med Commun. 2001;22:485–492
  77. Shaha AR, Byers RM, Terz JJ. Society of Surgical Oncology Practice Guidelines (Thyroid cancer surgical practice guidelines). Oncology. 1997;11:1228–1232
  78. Singer PA, Cooper DS, Daniels GH, et al. Treatment guidelines for patients with thyroid nodules and well-differentiate thyroid cancer (American Thyroid Association). Arch Intern Med. 1996;156:2165–2172
  79. Hay ID, Feld S, Garcia M, et al. AACE Clinical practice guidelines for the management of thyroid carcinoma. Endocr Pract. 1997;3:60–71
  80. Allen E, Owens SE, Waller ML. Differentiated thyroid cancer: Lobectomy and radioiodine, a suitable treatment for all cases?. Nucl Med Commun. 1999;20:983–989
  81. Kebebew E, Clark OH. Differentiated thyroid cancer: “complete” rational approach. World J Surg. 2000;24:942–951
  82. Newman KD, Black T, Heller G, et al. Differentiated thyroid cancer: determinants of disease progression in patients <21 years of age at diagnosis: A report from the Surgical Discipline Committee of the Children’s Cancer Group. Ann Surg. 1998;227:533–541
  83. Bingol-Kologlu M, Tanyel FC, Senocak ME, et al. Surgical treatment of differentiated thyroid cancer in children. Eur J Pediatr Surg. 2000;10:347–352
  84. Welch Dinauer CA, Tuttle RM, Robie DK, et al. Extensive surgery improves recurrence-free survival for children and young patients with class I papillary thyroid carcinoma. J Pediatr Surg. 1999;34:1799–1804
  85. Jarzab B, Handkiewicz Junak D, Wloch J, et al. Multivariate analysis of prognostic factors for differentiated thyroid carcinoma in children. Eur J Nucl Med. 2000;27:833–841
  86. Haveman JW, van Tol KM, Rouwe CW, et al. Surgical experience in children with differentiated thyroid carcinoma. Ann Surg Oncol. 2003;10:15–20
  87. Hallwirth U, Flores J, Kaserer K, et al. Differentiated thyroid cancer in children and adolescents: The importance of adequate surgery and review of the literature. Eur J Pediatr Surg. 1999;9:359–363
  88. La Quaglia MP, Black T, Holcomb GW, et al. Differentiated thyroid cancer: Clinical characteristics, treatment, and outcome in patients under 21 years of age who present with distant metastases (A report from the Surgical Discipline Committee of the Children’s Cancer Group). J Pediatr Surg. 2000;35:955–960
  89. Hung W, Sarlis N. Current controversies in the management of pediatric patients with well-differentiated nonmedullary thyroid cancer: a review. Thyroid. 2002;12:683–702
  90. Seidlin SM, Marinelli LD, Oshry E. Radioactive iodine therapy, effect of functioning metastases of adenocarcinoma of the thyroid. JAMA. 1946;132:838–847
  91. Schlumberger M, Tumbiana M, DeVathaire F, et al. Long-term treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1986;63:960
  92. DeGroot LJ, Kaplan EL, McCormick M, et al. Natural history, treatment and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71:414–424
  93. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgery and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418–428
  94. Reiners C, Farahati J. 131I therapy of thyroid cancer patients. QJ Nucl Med. 1999;43:324–335
  95. Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006;91:926–932
  96. Yeh SDJ, La Quaglia MP. 131I therapy for pediatric thyroid cancer. Semin Pediatr Surg. 1997;6:128–133
  97. Mazzaferri EL. Long-term outcome of patients with differentiated thyroid carcinoma: Effect of therapy. Endocr Pract. 2000;6:469–476
  98. Degroot LJ, Reilly M. Comparison of 30- and 50-mCi doses of iodine-131 for thyroid ablation. Ann Intern Med. 1982;96:51–53
  99. Maxon HR, Thomas SR, Hertzberg VS, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med. 1983;309:937–941
  100. Maxon HR. Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer. Q J Nucl Med. 1999;43:313–323
  101. Catz B, Petit D, Starr P. The diagnostic and therapeutic value of thyrotropic hormone and heavy dosage scintigram for the demonstration of thyroid cancer metastases. Am J Med Sci. 1959;237:158–164
  102. Nemec J, Rohling S, Zamrazil V, et al. Comparison of the distribution of diagnostic and thyroablative I-131 in the evaluation of differentiated thyroid cancers. J Nucl Med. 1979;20:92–97
  103. Waxman A, Ramanna L, Chapman L, et al. The significance of I-131 scan dose in patients with thyroid cancer: determination of ablation. J Nucl Med. 1981;22:861–865
  104. Mazzaferri EL. Empirically treating high serum thyroglobulin levels. J Nucl Med. 2005;46:1079–1088
  105. Chao M, Jiawei X, Anren K. Is Empiric 131I Therapy justified for patients with positive thyroglobulin and negative 131I wholebody scanning results?. J Nucl Med. 2005;46:1164–1170
  106. Luster M, Lippi F, Jarzab B, et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer. 2005;12:49–64
  107. Handscheid H, Lassmann M, Luster M, et al. Iodine kinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med. 2006;47:648–654
  108. Robbins RJ, Dreidger A, Magner J. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid. 2006;16:1121–1130
  109. Lau WF, Zacharin MR, Waters K, et al. Management of paediatric thyroid carcinoma: recent experience with recombinant human thyroid stimulating hormone in preparation for radioiodine therapy. Intern Med J. 2006;36:564–570
  110. Edmonds CJ, Smith T. The long term hazards of the treatment of thyroid cancer with radioiodine. Br J Radiol. 1986;59:45–51
  111. van Nostrand D, Neutze J, Atkins F. Side effects of “rational dose” iodine-131 therapy for metastatic well-differentiated thyroid carcinoma. J Nucl Med. 1986;27:1519–1527
  112. Maxon H, Thomas S, Samaratunga R. Dosimetric considerations in radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer. Thyroid. 1987;7:183–187
  113. Vini L, Al-Saadi A, Pratt B, et al. Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer. Postgrad Med J. 2002;78:92–93
  114. Raymond JP, Izembart M, Marliac V, et al. Temporary ovarian failure in thyroid cancer patients after thyroid remnant ablation with radioactive iodine. J Clin Endocr Metab. 1989;69:186–189
  115. Pacini F, Gasperi M, Fugazzola L, et al. Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine. J Nucl Med. 1994;35:1418–1422
  116. Dottorini ME. Genetic risk assessment after I-131 exposure: An opportunity and obligation for nuclear medicine. J Nucl Med. 1996;37:612–614
  117. Sarkar SD, Beierwaltes WH, Gill SP, et al. Subsequent fertility and birth histories of children and adolescents treated with I-131 for thyroid cancer. J Nucl Med. 1976;17:460–464
  118. Smith MB, Xue H, Takahashi H, et al. Iodine-131 thyroid ablation in female children and adolescents: long-term risk of infertility and birth defects. Ann Surg Oncol. 1994;1:128–131
  119. Schlumberger M, De Vathaire F, Ceccarelli C, et al. Outcome of pregnancy in women with thyroid carcinoma. J Endocrinol Invest. 1995;18:150–151
  120. Schlumberger M, De Vathaire F, Ceccarelli C, et al. Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J Nucl Med. 1996;37:606–612
  121. Ceccarelli C, Bencivelli W, Morciano D, et al. 131-I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: Results of a retrospective study. J Clin Endocrinol Metab. 2001;86:3512–3515
  122. Balan KK, Critchley M. Outcome of pregnancy following treatment of well differentiated thyroid cancer with 131-iodine. Br J Obstet Gynaecol. 1992;99:1021–1022
  123. Casara D, Rubello D, Saladini G, et al. Pregnancy after high therapeutic doses of iodine-131 in differentiated thyroid cancer: Potential risks and recommendations. Eur J Nucl Med. 1993;20:192–194
  124. Dottorini ME, Lomuscio G, Mazzucchelli L, et al. Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma. J Nucl Med. 1995;36:21–27
  125. Lin JD, Wang HS, Weng HF, et al. Outcome of pregnancy after radioiodine treatment for well differentiated thyroid carcinomas. J Endocrinol Invest. 1998;21:662–667
  126. Ayala C, Navarro E, Rodriguez JR, et al. Conception after I-131 therapy for differentiated thyroid cancer. Thyroid. 1998;8:1009–1011
  127. Handelsman DJ, Conway AJ, Donnelly PE, et al. Azoospermia after iodine-131 treatment for thyroid carcinoma. Br M J. 1980;281:1527
  128. Handelsman DJ, Turtle JR. Testicular damage after radioiodine (I-131) therapy for thyroid cancer. Clin Endocrinol. 1983;18:465–472
  129. Ahmed SR, Shalet SM. Gonadal damage due to radioactive iodine (I-131) treatment for thyroid carcinoma. Postgrad Med J. 1984;
  130. Gutierrez S, Carbonell E, Galofre P, et al. Cytogenic damage after I-131 treatment for hyperthyroidism and thyroid cancer: A study using the micronucleus test. European J Nucl Med. 1999;26(12):1589–1596
  131. Hagmar L, Brogger A, Hansteen I-L, et al. Cancer risk in humans predicted by increased levels of chromosome aberrations in lymphocytes: Nordic study group on the health risk of chromosome damage. Cancer Res. 1994;54:2919–2922
  132. Bonassi S, Abbondandolo A, Camurri L, et al. Are chromosome aberrations in circulating lymphocytes predictive of future cancer onset in humans? (Preliminary results of an Italian cohort study). Cancer Genet Cytogenet. 1995;79:133–135
  133. Brinker H, Hansen HS, Anderson AP. Induction of leukemia by 131-I treatment of thyroid cancer. Br J Cancer. 1973;28:232–237
  134. Holm LE, Dahlqvist I, Eng SM, et al. Malignant thyroid tumors after Iodine-131 therapy. N Engl J Med. 1980;303:188–191
  135. Hoffmann DA, McConahey WM, Fraumeni JF, et al. Cancer incidence following treatment of hyperthyroidism. Int J Epidemiol. 1982;11:218–224
  136. Hall P, Holm LE, Lundell G, et al. Cancer risks in thyroid cancer patients. Br J Cancer. 1991;64:159–163
  137. Hall P, Boice JD, Berg G, et al. Leukaemia incidence after iodine-131 exposure. Lancet. 1992;340:1–4
  138. Shimon I, Kneller A, Olchovosky D. Chronic myeloid leukaemia following 131-I treatment for thyroid carcinoma: A report of two cases and a review of the literature. Clin Endocrinol. 1995;43:651–654
  139. Laurenti L, Salutari P, Sica S, et al. Acute myeloid leukemia after iodine-131 treatment for thyroid disorders. Ann Hematol. 1998;6:271–272
  140. Green DM, Edge SB, Penetrante RB, et al. In situ breast carcinoma after treatment during adolescence for thyroid cancer with radioiodine. Med Pediatr Oncol. 1995;24:82–86
  141. Rubino C, De Vathaire RC, Dottorini ME, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer. 2003;89:1638–1644
  142. Kloos RT, Mazzaferri EL. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab. 2005;90:5047–5057
  143. Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?. J Clin Endocrinol Metab. 2002;87:1490–1498
  144. Durski JM, Weigel RJ, McDougall IR. Recombinant human thyrotropin (rhTSH) in the management of differentiated thyroid cancer. Nucl Med Commun. 2000;21:521–528
  145. Wang W, Macapinlac H, Larson SM, et al. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab. 1999;84:2291–2302
  146. Grunwald F, Kalicke T, Feine U, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of amulticentre study. Eur J Nucl Med. 1999;26:1547–1552
  147. Hooft L, Hoekstra OS, Deville W, et al. Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:3779–3786

PII: S0001-2998(07)00067-0

doi: 10.1053/j.semnuclmed.2007.05.001

Seminars in Nuclear Medicine
Volume 37, Issue 5 , Pages 340-356 , September 2007

Article Tools

* Image Usage & Resolution